Alternatives to Deep Science Ventures

A deep tech ecosystem providing lab space, expert training, and venture capital for startups.

Developing and industrializing cellulose-based superabsorbent materials as a fossil-free and biodegradable alternative.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Developing high-performance, compostable foams from bacterial cellulose to replace fossil-based plastics.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing circular biomass technology.

Cultivating wood directly into its final shape, 10,000x faster than forestry.

Enabling sustainable and scalable manufacturing of complex, high-value biomolecules through enzymatic biomanufacturing.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biotechnology company focused on developing cancer immunotherapies.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing novel therapeutics to restore gut lymphatic function.

Clinical-stage biotechnology company developing autologous neuron replacement medicines for neurodegenerative disorders.

A venture capital firm focused on deeptech investments.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing in vivo immunotherapies for autoimmune diseases and cancer.